Simpson Thacher represented KKR in connection with the sale of 3,450,000 shares of BridgeBio Pharma, Inc. The secondary offering, which was effected pursuant to a block trade, raised gross sale proceeds of approximately $208.6 million. The transaction closed on February 17, 2021.
BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio’s pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.
The Simpson Thacher team included Richard Fenyes and Nicholas Halliburton (Capital Markets); and James Rapp (Public Company Advisory Practice).
